UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond

Therapeutic Advances in Medical Oncology, 2019, Vol.11, p.1758835919880429-1758835919880429

2019

Volltextzugriff (PDF)

Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol

BMC cancer, 2018-04, Vol.18 (1), p.459-459, Article 459

2018

Volltextzugriff (PDF)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Breast cancer research : BCR, 2013-01, Vol.15 (5), p.R88-R88, Article R88

2013

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Breast cancer research and treatment, 2022-02, Vol.191 (3), p.565-576

2022

Volltextzugriff (PDF)

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Clinical cancer research, 2024-10, Vol.30 (19), p.4329-4338

2024

Volltextzugriff (PDF)

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

Future oncology (London, England), 2023-11, Vol.19 (35), p.2349-2359

2023

Volltextzugriff (PDF)

Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer

Current opinion in oncology, 2020-11, Vol.32 (6), p.575-584

2020

Volltextzugriff (PDF)

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients

Journal of clinical epidemiology, 2014-07, Vol.67 (7), p.811-820

2014

Volltextzugriff (PDF)

CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark

Clinical cancer research, 2015-09, Vol.21 (17), p.3813-3814

2015

Volltextzugriff (PDF)

Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy

Molecular neurobiology, 2019-07, Vol.56 (7), p.4741-4750

2019

Volltextzugriff (PDF)

A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer

BMC palliative care, 2022-05, Vol.21 (1), p.73-73, Article 73

2022

Volltextzugriff (PDF)

Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

Oncology, 2015-01, Vol.89 (2), p.79-87

2015

Volltextzugriff (PDF)

Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting

Scientific reports, 2015-11, Vol.5 (1), p.16252-16252, Article 16252

2015

Volltextzugriff (PDF)

Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

JCO precision oncology, 2022-11, Vol.6 (6), p.e2200309

2022

Volltextzugriff (PDF)

Patient–Caregiver Treatment Preference Discordance and Its Association With Caregiving Burden and Esteem

Innovation in aging, 2021-07, Vol.5 (3), p.igab020-igab020

2021

Volltextzugriff (PDF)

In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time?

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2130-2132

2011

Volltextzugriff (PDF)

Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce

JCO oncology practice, 2021-03, Vol.17 (3), p.e343-e354

2021

Volltextzugriff (PDF)

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

NPJ breast cancer, 2018-07, Vol.4 (1), p.19-7, Article 19

2018

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1360-1372

2017

Volltextzugriff (PDF)

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

SpringerPlus, 2015-10, Vol.4 (1), p.631-631, Article 631

2015

Volltextzugriff (PDF)

Goals of Care Among Patients With Advanced Cancer and Their Family Caregivers in the Last Years of Life

JAMA network open, 2024-04, Vol.7 (4), p.e245866-e245866

2024

Volltextzugriff (PDF)

Discordance Between Advanced Cancer Patients’ Perceived and Preferred Roles in Decision Making and its Association with Psychological Distress and Perceived Quality of Care

The patient : patient-centered outcomes research, 2021-09, Vol.14 (5), p.581-589

2021

Volltextzugriff (PDF)

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Journal of oncology practice, 2018-05, Vol.14 (5), p.281-289

2018

Volltextzugriff (PDF)

Immunotherapy as maintenance treatment in metastatic triple negative breast cancer

Journal of Cancer Metastasis and Treatment, 2021

2021

Volltextzugriff (PDF)

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Breast (Edinburgh), 2024-08, Vol.76, p.103756, Article 103756

2024

Volltextzugriff (PDF)

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(272)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Englisch
(294)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond

Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients

CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark

Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy

A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer

Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting

Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

Patient–Caregiver Treatment Preference Discordance and Its Association With Caregiving Burden and Esteem

In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time?

Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Goals of Care Among Patients With Advanced Cancer and Their Family Caregivers in the Last Years of Life

Discordance Between Advanced Cancer Patients’ Perceived and Preferred Roles in Decision Making and its Association with Psychological Distress and Perceived Quality of Care

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Immunotherapy as maintenance treatment in metastatic triple negative breast cancer

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Suchergebnisse filtern